Thryv Therapeutics Inc., a private, Montreal-based clinical-stage biopharmaceutical company, announced on September 3 that it has entered an exclusive, worldwide, royalty-bearing license agreement with three Spanish research institutions, the Spanish National Research Council (CSIC), the Autonomous University of Madrid (UAM), and the Fundación de la Universidad Autónoma de Madrid, covering a new class of SGK1 inhibitor compounds. The agreement, which took effect July 1, 2026, gives Thryv rights across all fields of use and territories, with the ability to sublicense. Thryv does not trade under a stock ticker, and this deal covers early-stage chemistry rather than a specific drug candidate, so the practical, near-term significance for investors is limited.
Why a Second Chemical Scaffold Matters
SGK1, short for serum and glucocorticoid-regulated kinase 1, is an enzyme involved in cell signaling that Thryv has been targeting with inhibitor drugs for cardiac and cardiometabolic disease. The company’s existing clinical candidates were all built from a single in-licensed chemical starting point, or scaffold, supported by a library of more than 500 synthesized variations and a patent estate covering that series. The newly licensed compounds come from a structurally distinct scaffold developed independently by the Spanish research groups, which Thryv describes as a genuinely separate starting point for drug design rather than a variation on its existing chemistry. In drug discovery, starting from a different chemical scaffold can matter because a molecule’s core structure influences properties like how well it penetrates different tissues, including the brain, which is relevant here since Thryv says the new series is intended to support development of SGK1 inhibitors for neurological disease, a goal its existing cardiac-focused chemistry was not designed around.
The Research Behind the License
The licensed compounds were developed by several named research groups: a medicinal chemistry team led by Ana Martínez and Carmen Gil and a cardiovascular team led by Eduardo Oliver Pérez, both at CSIC’s Centro de Investigaciones Biológicas Margarita Salas, along with a neurobiology group led by Isabel Lastres-Becker and a vascular pharmacology group led by Ana Briones Alonso, both at UAM. According to Thryv, published research has linked activated SGK1 to tau protein phosphorylation, the handling of misfolded proteins, neuroinflammatory signaling, and certain cellular stress-response pathways, all processes implicated in neurodegenerative conditions such as Parkinson’s disease, Alzheimer’s disease, and related tauopathies. That is Thryv’s own characterization of the scientific rationale behind the deal rather than data generated by the company itself, and no specific drug candidate targeting these diseases exists yet.
What the Company Is Saying
Thryv President and Chief Development Officer Debra Odink described SGK1 as an underexploited drug target and framed the license as giving the company a second, independent chemical foundation to pursue diseases its existing molecules were not built to reach, while its cardiac programs continue in parallel. That is the company’s own framing of the deal’s strategic value, and it reflects a broader, well-established idea in drug discovery: that no single chemical scaffold is well suited to every part of the body, and companies pursuing a target across multiple disease areas often need distinct chemistry for each one rather than repurposing the same molecule everywhere.
The Existing Pipeline Is Unaffected
On the existing pipeline, Thryv’s lead candidate, THRV-1268, an oral SGK1 inhibitor, is currently dosing patients in the WAVE II study, a registrational trial for Long QT Syndrome Type 2, a rare inherited heart rhythm disorder that can cause dangerous arrhythmias; the drug has also received FDA Fast Track designation, according to the company’s prior disclosures. A second study, ASPIRE-HF, a Phase 2a trial in heart failure with reduced ejection fraction, is planned to follow. Both of those programs are unaffected by this license and continue on their existing timelines.
A Multi-Year Timeline
For the newly licensed neurodegeneration-focused chemistry, Thryv says initial characterization work is starting immediately, but the company is not targeting a specific development candidate for nomination until 2027, and any compound reaching that stage would still need to complete preclinical testing and clear an investigational drug application before any human trial could begin. In practice, this means any therapy arising from this license is likely years away from clinical testing, let alone approval, even under a favorable timeline, and there is no guarantee the program will produce a viable drug candidate at all.
What’s Next
Thryv did not disclose the license’s financial terms beyond describing it as royalty-bearing; no upfront payment, royalty rate, or milestone structure was included in the release, and none is estimated here. This article covers an early-stage technology license and is not investment or medical advice.
Sources
Thryv Therapeutics Inc.: Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain’s CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease, PRNewswire, September 3, 2026.
Editorial Disclosure
This article is based on a press release issued by Thryv Therapeutics Inc. on September 3, 2026, distributed via PRNewswire. Thryv Therapeutics is a privately held company and does not trade under a stock ticker; no securities are discussed in this article. BioTech Stocks Daily was not compensated for this coverage. Statements regarding SGK1’s role in neurodegenerative disease and the strategic value of this license are characterizations from Thryv rather than independently verified findings; no drug candidate from the newly licensed chemistry has been nominated or tested in humans. This article is for informational and educational purposes only, does not constitute investment advice, and is not medical advice. Consult a qualified healthcare professional for medical guidance. See our full DISCLAIMER.
